MedTrace Logo

Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer

NCT01628757 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1400

Last updated 2016-05-17

No results posted yet for this study

Summary

Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies.

However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments.

This study is undertaken to build a model combine both clinical and genetic factors to predict the effects of neoadjuvant chemotherapy.

Conditions

Sponsors & Collaborators

  • Zhejiang University

    collaborator OTHER

  • Shandong University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Wuhan University

    collaborator OTHER

  • Hubei Women and Children's Hospital

    collaborator UNKNOWN

  • Wuhan General Hospital of Guangzhou Military Command

    collaborator OTHER

  • Xiangfan Central Hospital

    collaborator UNKNOWN

  • Wuhan Central Hospital

    collaborator OTHER

  • Hubei University for nationalities

    collaborator UNKNOWN

  • Ding Ma

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2018-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01628757 on ClinicalTrials.gov